NSTM - NovelStem International Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1200
0.0000 (0.00%)
At close: 12:29PM EST
Stock chart is not supported by your current browser
Previous Close0.1200
Open0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1200 - 0.1200
52 Week Range0.0500 - 0.1300
Volume300
Avg. Volume8,749
Market Cap1.452M
Beta (5Y Monthly)0.57
PE Ratio (TTM)0.43
EPS (TTM)0.2760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 01, 2018
1y Target Est2.50
  • GlobeNewswire

    NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic

    NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on stem-cell-based diagnostic technology to aid the selection of cancer therapeutic agents being developed by its Israel-based affiliate, NewStem Ltd., today announced it has completed a $1 million follow-on investment in NewStem, increasing its ownership in NewStem to 27.3% from 20%. The additional investment was made following NewStem’s successful, on-time completion of the first milestone requirements established at the time of its initial investment in July 2018. This included set up and analysis of resistance to five anti-cancer treatments that are the standard-of-care, enabling it to further develop diagnostics for identifying patient resistance to those treatments.

  • GlobeNewswire

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.

  • GlobeNewswire

    NovelStem Provides Shareholder Update

    NovelStem International Corp. (OTC Pink: NSTM) is focused on the substantial commercial potential of stem-cell-based diagnostic technology to aid the selection of cancer chemotherapy agents, which technology is being developed by its 20%-owned affiliate, NewStem Ltd. NovelStem expects to provide a shareholder update on NewStem’s progress within the next month. NovelStem announced today that its 50% owned Netco Partners unit has executed an agreement with Hanover Square Press, an imprint of HarperCollins, to relaunch the “Net Force” book series. Hanover Square Press acquired publishing rights to four novels and four e-novellas in the series and anticipates the first launch, Net Force: Dark Web, to take place in October with one novel and one e-novella expected per year.